img

Global Recombinant DNA Vaccine Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Recombinant DNA Vaccine Market Insights, Forecast to 2034

Recombinant DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines.
Global Recombinant DNA Vaccine market is expected to reach to US$ 214 million in 2024, with a positive growth of %, compared with US$ 186 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Recombinant DNA Vaccine industry is evaluated to reach US$ 502.8 million in 2029. The CAGR will be 15.3% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Recombinant DNA Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant DNA Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Merck
GSK
Sanofi
Zoties
Elanco
Boehringer-Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Segment by Type
Recombinant Protein Vaccine
Gene-Based Vaccine

Segment by Application


Human
Animal

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant DNA Vaccine plant distribution, commercial date of Recombinant DNA Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant DNA Vaccine introduction, etc. Recombinant DNA Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Recombinant DNA Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Recombinant DNA Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant DNA Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Recombinant Protein Vaccine
1.2.3 Gene-Based Vaccine
1.3 Market by Application
1.3.1 Global Recombinant DNA Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Human
1.3.3 Animal
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant DNA Vaccine Sales Estimates and Forecasts 2018-2029
2.2 Global Recombinant DNA Vaccine Revenue by Region
2.2.1 Global Recombinant DNA Vaccine Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Recombinant DNA Vaccine Revenue by Region (2018-2024)
2.2.3 Global Recombinant DNA Vaccine Revenue by Region (2024-2029)
2.2.4 Global Recombinant DNA Vaccine Revenue Market Share by Region (2018-2029)
2.3 Global Recombinant DNA Vaccine Sales Estimates and Forecasts 2018-2029
2.4 Global Recombinant DNA Vaccine Sales by Region
2.4.1 Global Recombinant DNA Vaccine Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Recombinant DNA Vaccine Sales by Region (2018-2024)
2.4.3 Global Recombinant DNA Vaccine Sales by Region (2024-2029)
2.4.4 Global Recombinant DNA Vaccine Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Recombinant DNA Vaccine Sales by Manufacturers
3.1.1 Global Recombinant DNA Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global Recombinant DNA Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant DNA Vaccine in 2022
3.2 Global Recombinant DNA Vaccine Revenue by Manufacturers
3.2.1 Global Recombinant DNA Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Recombinant DNA Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant DNA Vaccine Revenue in 2022
3.3 Global Key Players of Recombinant DNA Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Recombinant DNA Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Recombinant DNA Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Recombinant DNA Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Recombinant DNA Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Recombinant DNA Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant DNA Vaccine Sales by Type
4.1.1 Global Recombinant DNA Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global Recombinant DNA Vaccine Forecasted Sales by Type (2024-2029)
4.1.3 Global Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Recombinant DNA Vaccine Revenue by Type
4.2.1 Global Recombinant DNA Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Recombinant DNA Vaccine Forecasted Revenue by Type (2024-2029)
4.2.3 Global Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant DNA Vaccine Price by Type
4.3.1 Global Recombinant DNA Vaccine Price by Type (2018-2024)
4.3.2 Global Recombinant DNA Vaccine Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Recombinant DNA Vaccine Sales by Application
5.1.1 Global Recombinant DNA Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global Recombinant DNA Vaccine Forecasted Sales by Application (2024-2029)
5.1.3 Global Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Recombinant DNA Vaccine Revenue by Application
5.2.1 Global Recombinant DNA Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Recombinant DNA Vaccine Forecasted Revenue by Application (2024-2029)
5.2.3 Global Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant DNA Vaccine Price by Application
5.3.1 Global Recombinant DNA Vaccine Price by Application (2018-2024)
5.3.2 Global Recombinant DNA Vaccine Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Recombinant DNA Vaccine Market Size by Type
6.1.1 US & Canada Recombinant DNA Vaccine Sales by Type (2018-2029)
6.1.2 US & Canada Recombinant DNA Vaccine Revenue by Type (2018-2029)
6.2 US & Canada Recombinant DNA Vaccine Market Size by Application
6.2.1 US & Canada Recombinant DNA Vaccine Sales by Application (2018-2029)
6.2.2 US & Canada Recombinant DNA Vaccine Revenue by Application (2018-2029)
6.3 US & Canada Recombinant DNA Vaccine Market Size by Country
6.3.1 US & Canada Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Recombinant DNA Vaccine Sales by Country (2018-2029)
6.3.3 US & Canada Recombinant DNA Vaccine Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Recombinant DNA Vaccine Market Size by Type
7.1.1 Europe Recombinant DNA Vaccine Sales by Type (2018-2029)
7.1.2 Europe Recombinant DNA Vaccine Revenue by Type (2018-2029)
7.2 Europe Recombinant DNA Vaccine Market Size by Application
7.2.1 Europe Recombinant DNA Vaccine Sales by Application (2018-2029)
7.2.2 Europe Recombinant DNA Vaccine Revenue by Application (2018-2029)
7.3 Europe Recombinant DNA Vaccine Market Size by Country
7.3.1 Europe Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Recombinant DNA Vaccine Sales by Country (2018-2029)
7.3.3 Europe Recombinant DNA Vaccine Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Recombinant DNA Vaccine Market Size
8.1.1 China Recombinant DNA Vaccine Sales (2018-2029)
8.1.2 China Recombinant DNA Vaccine Revenue (2018-2029)
8.2 China Recombinant DNA Vaccine Market Size by Application
8.2.1 China Recombinant DNA Vaccine Sales by Application (2018-2029)
8.2.2 China Recombinant DNA Vaccine Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Recombinant DNA Vaccine Market Size by Type
9.1.1 Asia Recombinant DNA Vaccine Sales by Type (2018-2029)
9.1.2 Asia Recombinant DNA Vaccine Revenue by Type (2018-2029)
9.2 Asia Recombinant DNA Vaccine Market Size by Application
9.2.1 Asia Recombinant DNA Vaccine Sales by Application (2018-2029)
9.2.2 Asia Recombinant DNA Vaccine Revenue by Application (2018-2029)
9.3 Asia Recombinant DNA Vaccine Sales by Region
9.3.1 Asia Recombinant DNA Vaccine Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Recombinant DNA Vaccine Revenue by Region (2018-2029)
9.3.3 Asia Recombinant DNA Vaccine Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Recombinant DNA Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Recombinant DNA Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Overview
11.1.3 Merck Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Merck Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 GSK Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Sanofi Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Zoties
11.4.1 Zoties Company Information
11.4.2 Zoties Overview
11.4.3 Zoties Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Zoties Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Zoties Recent Developments
11.5 Elanco
11.5.1 Elanco Company Information
11.5.2 Elanco Overview
11.5.3 Elanco Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Elanco Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Elanco Recent Developments
11.6 Boehringer-Ingelheim
11.6.1 Boehringer-Ingelheim Company Information
11.6.2 Boehringer-Ingelheim Overview
11.6.3 Boehringer-Ingelheim Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Boehringer-Ingelheim Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Boehringer-Ingelheim Recent Developments
11.7 Indian Immunologicals
11.7.1 Indian Immunologicals Company Information
11.7.2 Indian Immunologicals Overview
11.7.3 Indian Immunologicals Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Indian Immunologicals Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Indian Immunologicals Recent Developments
11.8 Plumbline Life Sciences
11.8.1 Plumbline Life Sciences Company Information
11.8.2 Plumbline Life Sciences Overview
11.8.3 Plumbline Life Sciences Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Plumbline Life Sciences Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Plumbline Life Sciences Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant DNA Vaccine Industry Chain Analysis
12.2 Recombinant DNA Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant DNA Vaccine Production Mode & Process
12.4 Recombinant DNA Vaccine Sales and Marketing
12.4.1 Recombinant DNA Vaccine Sales Channels
12.4.2 Recombinant DNA Vaccine Distributors
12.5 Recombinant DNA Vaccine Customers
13 Market Dynamics
13.1 Recombinant DNA Vaccine Industry Trends
13.2 Recombinant DNA Vaccine Market Drivers
13.3 Recombinant DNA Vaccine Market Challenges
13.4 Recombinant DNA Vaccine Market Restraints
14 Key Findings in The Global Recombinant DNA Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Recombinant DNA Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Recombinant Protein Vaccine
Table 3. Major Manufacturers of Gene-Based Vaccine
Table 4. Global Recombinant DNA Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Recombinant DNA Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Recombinant DNA Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Recombinant DNA Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Recombinant DNA Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Recombinant DNA Vaccine Revenue Market Share by Region (2024-2029)
Table 10. Global Recombinant DNA Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Recombinant DNA Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global Recombinant DNA Vaccine Sales by Region (2024-2029) & (K Units)
Table 13. Global Recombinant DNA Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Recombinant DNA Vaccine Sales Market Share by Region (2024-2029)
Table 15. Global Recombinant DNA Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Recombinant DNA Vaccine Sales Share by Manufacturers (2018-2024)
Table 17. Global Recombinant DNA Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Recombinant DNA Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Recombinant DNA Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Recombinant DNA Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Recombinant DNA Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Recombinant DNA Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant DNA Vaccine as of 2022)
Table 23. Global Key Manufacturers of Recombinant DNA Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Recombinant DNA Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Recombinant DNA Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Recombinant DNA Vaccine Sales by Type (2018-2024) & (K Units)
Table 28. Global Recombinant DNA Vaccine Sales by Type (2024-2029) & (K Units)
Table 29. Global Recombinant DNA Vaccine Sales Share by Type (2018-2024)
Table 30. Global Recombinant DNA Vaccine Sales Share by Type (2024-2029)
Table 31. Global Recombinant DNA Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Recombinant DNA Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Recombinant DNA Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Recombinant DNA Vaccine Revenue Share by Type (2024-2029)
Table 35. Recombinant DNA Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Recombinant DNA Vaccine Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Recombinant DNA Vaccine Sales by Application (2018-2024) & (K Units)
Table 38. Global Recombinant DNA Vaccine Sales by Application (2024-2029) & (K Units)
Table 39. Global Recombinant DNA Vaccine Sales Share by Application (2018-2024)
Table 40. Global Recombinant DNA Vaccine Sales Share by Application (2024-2029)
Table 41. Global Recombinant DNA Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Recombinant DNA Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Recombinant DNA Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Recombinant DNA Vaccine Revenue Share by Application (2024-2029)
Table 45. Recombinant DNA Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Recombinant DNA Vaccine Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Recombinant DNA Vaccine Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Recombinant DNA Vaccine Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Recombinant DNA Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Recombinant DNA Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Recombinant DNA Vaccine Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Recombinant DNA Vaccine Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Recombinant DNA Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Recombinant DNA Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Recombinant DNA Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Recombinant DNA Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Recombinant DNA Vaccine Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 60. Europe Recombinant DNA Vaccine Sales by Type (2018-2024) & (K Units)
Table 61. Europe Recombinant DNA Vaccine Sales by Type (2024-2029) & (K Units)
Table 62. Europe Recombinant DNA Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Recombinant DNA Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Recombinant DNA Vaccine Sales by Application (2018-2024) & (K Units)
Table 65. Europe Recombinant DNA Vaccine Sales by Application (2024-2029) & (K Units)
Table 66. Europe Recombinant DNA Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Recombinant DNA Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Recombinant DNA Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Recombinant DNA Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Recombinant DNA Vaccine Sales by Country (2018-2024) & (K Units)
Table 72. Europe Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 73. China Recombinant DNA Vaccine Sales by Type (2018-2024) & (K Units)
Table 74. China Recombinant DNA Vaccine Sales by Type (2024-2029) & (K Units)
Table 75. China Recombinant DNA Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Recombinant DNA Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Recombinant DNA Vaccine Sales by Application (2018-2024) & (K Units)
Table 78. China Recombinant DNA Vaccine Sales by Application (2024-2029) & (K Units)
Table 79. China Recombinant DNA Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Recombinant DNA Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Recombinant DNA Vaccine Sales by Type (2018-2024) & (K Units)
Table 82. Asia Recombinant DNA Vaccine Sales by Type (2024-2029) & (K Units)
Table 83. Asia Recombinant DNA Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Recombinant DNA Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Recombinant DNA Vaccine Sales by Application (2018-2024) & (K Units)
Table 86. Asia Recombinant DNA Vaccine Sales by Application (2024-2029) & (K Units)
Table 87. Asia Recombinant DNA Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Recombinant DNA Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Recombinant DNA Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Recombinant DNA Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Recombinant DNA Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Recombinant DNA Vaccine Sales by Region (2018-2024) & (K Units)
Table 93. Asia Recombinant DNA Vaccine Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 107. Merck Company Information
Table 108. Merck Description and Major Businesses
Table 109. Merck Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Merck Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Merck Recent Developments
Table 112. GSK Company Information
Table 113. GSK Description and Major Businesses
Table 114. GSK Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. GSK Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. GSK Recent Developments
Table 117. Sanofi Company Information
Table 118. Sanofi Description and Major Businesses
Table 119. Sanofi Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Sanofi Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Sanofi Recent Developments
Table 122. Zoties Company Information
Table 123. Zoties Description and Major Businesses
Table 124. Zoties Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Zoties Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Zoties Recent Developments
Table 127. Elanco Company Information
Table 128. Elanco Description and Major Businesses
Table 129. Elanco Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Elanco Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Elanco Recent Developments
Table 132. Boehringer-Ingelheim Company Information
Table 133. Boehringer-Ingelheim Description and Major Businesses
Table 134. Boehringer-Ingelheim Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Boehringer-Ingelheim Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Boehringer-Ingelheim Recent Developments
Table 137. Indian Immunologicals Company Information
Table 138. Indian Immunologicals Description and Major Businesses
Table 139. Indian Immunologicals Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Indian Immunologicals Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Indian Immunologicals Recent Developments
Table 142. Plumbline Life Sciences Company Information
Table 143. Plumbline Life Sciences Description and Major Businesses
Table 144. Plumbline Life Sciences Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Plumbline Life Sciences Recombinant DNA Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Plumbline Life Sciences Recent Developments
Table 147. Key Raw Materials Lists
Table 148. Raw Materials Key Suppliers Lists
Table 149. Recombinant DNA Vaccine Distributors List
Table 150. Recombinant DNA Vaccine Customers List
Table 151. Recombinant DNA Vaccine Market Trends
Table 152. Recombinant DNA Vaccine Market Drivers
Table 153. Recombinant DNA Vaccine Market Challenges
Table 154. Recombinant DNA Vaccine Market Restraints
Table 155. Research Programs/Design for This Report
Table 156. Key Data Information from Secondary Sources
Table 157. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant DNA Vaccine Product Picture
Figure 2. Global Recombinant DNA Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Recombinant DNA Vaccine Market Share by Type in 2022 & 2029
Figure 4. Recombinant Protein Vaccine Product Picture
Figure 5. Gene-Based Vaccine Product Picture
Figure 6. Global Recombinant DNA Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Recombinant DNA Vaccine Market Share by Application in 2022 & 2029
Figure 8. Human
Figure 9. Animal
Figure 10. Recombinant DNA Vaccine Report Years Considered
Figure 11. Global Recombinant DNA Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Recombinant DNA Vaccine Revenue 2018-2029 (US$ Million)
Figure 13. Global Recombinant DNA Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global Recombinant DNA Vaccine Revenue Market Share by Region (2018-2029)
Figure 15. Global Recombinant DNA Vaccine Sales 2018-2029 ((K Units)
Figure 16. Global Recombinant DNA Vaccine Sales Market Share by Region (2018-2029)
Figure 17. US & Canada Recombinant DNA Vaccine Sales YoY (2018-2029) & (K Units)
Figure 18. US & Canada Recombinant DNA Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe Recombinant DNA Vaccine Sales YoY (2018-2029) & (K Units)
Figure 20. Europe Recombinant DNA Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China Recombinant DNA Vaccine Sales YoY (2018-2029) & (K Units)
Figure 22. China Recombinant DNA Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) Recombinant DNA Vaccine Sales YoY (2018-2029) & (K Units)
Figure 24. Asia (excluding China) Recombinant DNA Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales YoY (2018-2029) & (K Units)
Figure 26. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The Recombinant DNA Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Recombinant DNA Vaccine in the World: Market Share by Recombinant DNA Vaccine Revenue in 2022
Figure 29. Global Recombinant DNA Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
Figure 31. Global Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
Figure 32. Global Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
Figure 33. Global Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
Figure 35. US & Canada Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
Figure 36. US & Canada Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
Figure 37. US & Canada Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada Recombinant DNA Vaccine Revenue Share by Country (2018-2029)
Figure 39. US & Canada Recombinant DNA Vaccine Sales Share by Country (2018-2029)
Figure 40. U.S. Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 41. Canada Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 42. Europe Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
Figure 43. Europe Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
Figure 44. Europe Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
Figure 45. Europe Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
Figure 46. Europe Recombinant DNA Vaccine Revenue Share by Country (2018-2029)
Figure 47. Europe Recombinant DNA Vaccine Sales Share by Country (2018-2029)
Figure 48. Germany Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 49. France Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 50. U.K. Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 51. Italy Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 52. Russia Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 53. China Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
Figure 54. China Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
Figure 55. China Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
Figure 56. China Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
Figure 57. Asia Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
Figure 58. Asia Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
Figure 59. Asia Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
Figure 60. Asia Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
Figure 61. Asia Recombinant DNA Vaccine Revenue Share by Region (2018-2029)
Figure 62. Asia Recombinant DNA Vaccine Sales Share by Region (2018-2029)
Figure 63. Japan Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 64. South Korea Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 65. China Taiwan Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 66. Southeast Asia Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 67. India Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 68. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
Figure 69. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
Figure 71. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Recombinant DNA Vaccine Revenue Share by Country (2018-2029)
Figure 73. Middle East, Africa and Latin America Recombinant DNA Vaccine Sales Share by Country (2018-2029)
Figure 74. Brazil Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 75. Mexico Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 76. Turkey Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 77. Israel Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 78. GCC Countries Recombinant DNA Vaccine Revenue (2018-2029) & (US$ Million)
Figure 79. Recombinant DNA Vaccine Value Chain
Figure 80. Recombinant DNA Vaccine Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed